Ivermectin as a SARS-CoV-2 Pre-Exposure Prophylaxis Method in Healthcare Workers: A Propensity Score-Matched Retrospective Cohort Study
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
- Evaluated articles (Rapid Reviews Infectious Diseases)
Abstract
Article activity feed
-
Alfonso J. Rodriguez-Morales
Review 1: "Retrospective Cohort Study of Ivermectin as a SARS-CoV-2 Pre-exposure Prophylaxis Method in Healthcare Workers"
-
Strength of evidence
Reviewer: A J. Rodriguez-Morales (Fundacion Universitaria Autonoma de las Americas) | 📕 ◻️◻️◻️◻️
-
-
SciScore for 10.1101/2021.04.10.21255248: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: The participants who adhered to the Ivermectin prophylaxis program and signed the informed consent and had a minimum age of 18 years old, were included in the intervention group only if: 1. received the first dose of Ivermectin during the first week of the study; 2. complied with a minimum of 2 doses of Ivermectin during the 4 weeks of the study; 3. the difference in days between 2 doses was not greater than 14 days. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable The following healthcare personnel were excluded from the Ivermectin prophylaxis program: pregnant or suspected pregnant women; women … SciScore for 10.1101/2021.04.10.21255248: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: The participants who adhered to the Ivermectin prophylaxis program and signed the informed consent and had a minimum age of 18 years old, were included in the intervention group only if: 1. received the first dose of Ivermectin during the first week of the study; 2. complied with a minimum of 2 doses of Ivermectin during the 4 weeks of the study; 3. the difference in days between 2 doses was not greater than 14 days. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable The following healthcare personnel were excluded from the Ivermectin prophylaxis program: pregnant or suspected pregnant women; women breastfeeding; patients receiving coumarin anticoagulants; those allergic to Ivermectin. Table 2: Resources
Software and Algorithms Sentences Resources The statistical analysis was done with IBM SPSS and RStudio 4.0.4 SPSSsuggested: (SPSS, RRID:SCR_002865)RStudiosuggested: (RStudio, RRID:SCR_000432)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04832945 Completed SARS-CoV-2 Pre-exposure Prophylaxis With Ivermectin Retrospe… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
